Minor histocompatibility antigens in GVL

Allogeneic Immunotherapy for Malignant Diseases

Volumn , Issue , 2000, Pages 119-133

  Mutis, Tuna ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0742333939     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (46)

1. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996; 8: 75-81.
2. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-1480.
3. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bischop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard VH, Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single aminoacid polymorphism. Science. 1998; 279:1054-1057.
4. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shaba-nowitz J, Agulnik AI, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard VH. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269:1588-1590.
5. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW, Shabanowitz J, Pierce R, Agulnik AI, Bishop CE, Hunt DF, Goulmy E, Engelhard VH. The HLA-A0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6:273-281.
6. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157:125-140.
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-562.
8. Gratwohl A, Hermans J, Apperley JF, Arcese W, Bacigalupo A, Bandini G, di-Bartolomeo P, Boogaerts M, Bosi A, Carreras E, Devergie A, Ferrant A, Fibbe WE, Frassoni F, Gahrton G, Goldman JM, Iriondo A, Jacobsen N, Kolb HJ, Link H, Michallet M, Prentice HG, Reiffers J, van Rhee F, Ruutu T, Schwaighofer H, Ver-nant JP, de Witte T, Niederwieser D. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia: Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995; 86:813-818.
9. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76:2462-2465.
10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermuller J, de Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-2050.
11. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrrow transplantation. Bone Marrow Transplant 1996; 18:975-980.
12. Bar BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, Linders EH, De Witte T. Donor leukocyte infusions for chronic myelold leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993, 11: 513-519.
13. Bunjes D, Theobald M, Hertenstein B, Wiesneth M, Novotny J, Arnold R, Heimpel H. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transplant 1995; 15:713-719.
14. Cullis JO, Jiang YZ Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myelold leukemia in relapse after allogeneic bone marrow transplantation (letter). Blood 1995; 79:1379-1381.
15. Kell F, Hass OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Nieder-wieser D, Hoecker P, Greinix HT. Donor leukocyte infusions for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89:3113-3117.
16. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195-2204.
17. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82:2310-2318.
18. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100-106.
19. Russell LA, Jacobsen N, Heilmann C, Simonsen AC, Christensen LD, Vlndelov LL. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients. Bone Marrow Transplant 1996; 18:411-414.
20. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 1993; 11:109-111.
21. Tzeng CH, Lin JS, Lee JC, Yung CH, Hu HY, Chen PM. Transfusion of donor peripheral blood buffy coat cells as effective treatment for relapsed acute leukemia after transplantation of allogeneic bone marrow or peripheral blood stem cells from the same donor. Transfusion 1996; 36:685-690.
22. Fores R, Diez-Martin JL, Briz M, Cabrera JR, Sanjuan I, Regidor C, Garcia-Talavera J, Fernandez MN. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17:439-441.
23. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Hubner G, Heimpel H, Arnold R. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogenic bone marrow transplantation. Transplantation 1993; 56:1114-1118.
24. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12:125-129.
25. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997; 157:167-176.
26. Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991; 8:253-258.
27. van Els CA, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens: I. Absence of correlation with cytotoxic effector cells. Transplantation 1990; 50:62-66.
28. van Els CA, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens: II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990; 50:67-71.
29. van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus- leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10:181-183.
30. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gas-sner C, Schiller L, Petersen F, Niederwieser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88:1501-1508.
31. Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor CG, de Witte TM, van de Wiel-van Kemenade E. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997; 158:560-565.
32. Faber LM, van Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JHF. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogenic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86:2821-2828.
33. Lachance S, Le Gouvello S, Roudot F, Kuentz M, Bernaudin F, Beaujean F, Bierling P, Cordonnier C, Farcet JP, Vernant JP. Predictive value of host-specific donor helper T-cell precursor frequency for acute graft-versus-host disease and relapse in HLA-identical siblings receiving allogeneic bone marrow transplantation for hematological malignancies. Transplantation 1997; 64:1147-1152.
34. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, Mavroudis DA, van Rhee F, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14:517-524.
35. Hoffmann T, Theobald M, Bunjes D, Weiss M, Heimpel H, Heit W. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993; 12:1-8.
36. Oettel KR, Wesly OH, Albertinl MR, Hank JA, Illopolis O, Sosman JA, Voelkerding K, Wu SQ, Clark SS, Sondel PM. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1 +) human leukemia lines can also recognize Ph1- cells from the same patient. Blood 1994; 83:3390-3402.
37. Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176:1283-1289.
38. Falkenburg JHF, Faber LM, van den Elshout M, van Luxemburg-Heijs SA, Hooft-man-den Otter A, Smit WM, Voogt PJ, Willemze R. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 1993; 14:305-309.
39. Falkenburg JHF, Wafelman AR, van Bergen CAM, Bongaerts R, Lurvink EGA, Posthuma EFM, Smit WM, Joosten P, Landegent JE, Kluin-Nelemans JC, Fibbe WE, Willemze R. Leukemia-reactive cytotoxic T lymphocytes (CTL) induce complete remission in a patients with refractory accelerated chronic myeloid leukemia (CML) (abstr). 1997; 90(suppl 1):589.
40. Mutis T, Schrama E, Melief CJM, Goulmy E. CD80 transfected acute myeloid leukemia cells induce primary T cell responses directed at patient specific minor histocompatibility antigens and leukemia associated antigens. Blood 1998; 92:1677-1684.
41. de Bueger M, Bakker A, van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149:1788-1794.
42. Falkenburg JHF, Goselink HM, van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM, de Kroon J, Brand A, Flbbe WE, Willemze R, Goulmy E. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174:27-33.
43. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SA, Willemze R, Falkenburg JHF. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4 + minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995; 96:877-883.
44. Niederwieser D, Grassegger A, Aubock J, Herold M, Nachbaur D, Rosenmayr A, Gachter A, Nussbaumer W, Gaggl S, Ritter M, Huber C, Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993; 81:2200-2208.
45. van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YM, van Luxem-burg-Heijs SA, Goselink HM, Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83:1060-1066.
46. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93:2336-2341.